(Alliance News) - PharmaNutra Spa on Friday reported its fiscal year 2023 results, which closed with a profit of EUR12.8 million from EUR15.1 million in the previous year.

Consolidated sales revenue in 2023 was EUR100.2 million, up 21 percent from EUR83.4 million in 2022.

Ebitda stood at EUR26.5 million from EUR24.4 million in 2022, up 8.7 percent, and was a margin of 26 percent from one of 29 percent in 2022 on total revenues.

Net financial position shows a negative balance of EUR2.6 million from a positive EUR10.6 million in 2022.

As for the future, "the PharmaNutra Group will work as always to achieve ambitious goals, maintaining a constant focus on the efficient management of its economic and financial structure to respond flexibly and immediately to the uncertainties of 2024, strong with a unique product portfolio and clear and effective development strategies to continue a solid growth path," the statement said.

The board also resolved to propose to the shareholders' meeting the repurchase of treasury shares for a maximum consideration of EUR3.0 million.

PharmaNutra's stock closed Friday in the red by 0.2 percent at EUR59.20 per share.

By Chiara Bruschi, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2024 Alliance News IS Italian Service Ltd. All rights reserved.